Clinical Trials Search
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
The purpose of this study is to find out if an investigational drug called PV-10, given in combination with another drug called pembrolizumab (also called Keytruda®) can help people with melanoma.
The primary objective of the initial, single-arm Phase 1b portion of the study, is to assess safety and preliminary efficacy (objective response rate and progression free survival) of the combination (i.e., PV-10 + pembrolizumab) in treating metastatic melanoma. Potential immunomodulatory impact of study treatment will also be assessed.
PV-10 (); Pembrolizumab (Keytruda)